UN Biopiracy Treaty: Indigenous Knowledge Patent Reform

Synthetic biology fundamentally challenges existing international frameworks for genetic resource governance, particularly the Convention on Biological Diversity established in the early 1990s. Originally designed to ensure indigenous communities received benefits from genetic resources they had traditionally used, the framework assumed physical specimens must be collected. However, digital sequence information enables genetic material to be synthesized without collecting specimens, fundamentally changing access dynamics. This creates complications for determining who should receive licensing benefits, as pharmaceutical companies could theoretically synthesize compounds based on genetic sequences without engaging with local communities holding traditional knowledge. Examples include vanilla synthesis, which could undermine livelihoods of farmers in Madagascar, and other agricultural products. The CBD is struggling to address these challenges, as synthetic biology undercuts principles on which the convention was originally based, requiring entirely new approaches to access and benefit sharing.

This segment explains how DNA serves as the raw resource for genetic engineering, with biotechnology companies taking DNA codes from nature to reprogram living organisms. The original samples were taken from communities - farmers, indigenous communities, and ocean communities - often by those communities for generations. The biotechnology industry has been accused of biopiracy - profiting from resources taken from stewards of biodiversity. The shift from physical genetic material to digital sequence information (DNA sequences stored in databases) has complicated the original Access and Benefit Sharing framework. The answer that emerged was to pay into the Carly Fund rather than directly to communities, which breaks the connection between those who looked after genetic resources and those exploiting them.

Digital Sequence Information refers to nucleotide sequence data and related omics data that can be downloaded online without physical access to genetic resources. This emerged as a critical challenge because the existing ABS framework was designed for physical genetic resources, not digital data. The concern is that sequencing and publishing genomic data online may bypass the benefit-sharing obligations intended under the CBD and Nagoya Protocol, potentially constituting a form of 'bio-piracy' where countries providing genetic resources receive no benefits despite their contribution to the data.

Digital Sequence Information (DSI) refers to genetic sequences (DNA/RNA) that can be transferred electronically, enabling global access without physical sample movement. The term emerged around 2010 when cheaper sequencing technology enabled digital transfers that evaded access and benefit-sharing laws. It combines 'digital' (mobility/processability) with 'sequence information' (actual genetic data). The Convention on Biological Diversity (CBD), adopted in 1992, established three pillars: conservation, sustainable use, and fair benefit-sharing. Traditional biopiracy involved stealing physical samples; DSI enables 'data piracy' through open-access databases. Case studies illustrate failures: Nipah virus (1998-1999) - Malaysian scientists identified the virus, shared samples internationally, but diagnostic kits and patents were commercialized in the US without benefiting Malaysia. Similarly, Ebola sequence data from West Africa enabled Regeneron to receive $400M+ in orders while avoiding benefit-sharing obligations. These cases demonstrate how open science principles conflict with equitable benefit distribution when no enforceable frameworks exist for digital genetic resources.

Digital Sequence Information (DSI) refers to the digital data generated from sequencing genomes or proteins, which has revolutionized biological science by enabling rapid disease research, food authentication, and agricultural innovation; however, the current system of storing DSI in three public databases (Japan, Europe, and the US) with open access policies has created international disagreements about benefit-sharing, as countries fear losing economic opportunities while pharmaceutical companies and other entities profit from genetic resources without equitable compensation to traditional knowledge holders and source countries.

Non-monetary benefits should be emphasized in ABS agreements because many countries still think about money at most of the time. While monetary benefits are good if they exist, non-monetary benefits in practice probably deliver much more for the country. It is a good idea to implement an ABS policy in your institute so everybody knows what is expected of them.

Benefit-sharing under ABS encompasses both financial and non-financial components. Financial benefits include royalties, licensing fees, and revenue-sharing arrangements derived from commercial products developed using genetic resources. Non-financial benefits include technology transfer, capacity building programs, training opportunities, infrastructure development, and knowledge sharing initiatives. Both types of benefits must be considered when designing ABS frameworks to ensure comprehensive and equitable benefit distribution to all stakeholders, particularly local communities.

The Nagoya Protocol on Access and Benefit-Sharing (ABS) is a key component of the Convention on Biological Diversity that ensures fair and equitable sharing of benefits arising from the utilization of genetic resources. Implementation requires developing national ABS frameworks, building stakeholder capacity, and establishing trust between genetic resource users and providers. Successful ABS implementation enables biodiversity-rich countries to receive monetary and non-monetary benefits (such as technology transfer and capacity building) while promoting biodiversity conservation. Case studies from Colombia, China, Cuba, and Panama demonstrate how ABS mechanisms can channel benefits to local communities and support sustainable development goals.

The CBD commissioned a study to develop indicators for measuring ABS outcomes. The monetary benefit indicator is the amount of money received bilaterally and multilaterally in accordance with internationally agreed ABS instruments. The non-monetary benefit indicator is the number of research and development results from ABS agreements shared. This is important because it links different ABS instruments together. For monetary benefits, countries will need to keep national records, which will be challenging for some countries but necessary. For multilateral instruments, countries can just report on the fund.

Antigua and Barbuda ratified the protocol early and passed legislation in 2015, creating systematic research permitting processes with compliance measures including blacklisting and repatriation requirements. St. Kitts and Nevis ratified in September 2018 and began developing draft legislation. These cases demonstrate that proper ABS frameworks enable controlled bioprospecting while ensuring both local providers and external researchers benefit, transforming informal systems into regulated, transparent processes.

The Traditional Knowledge Digital Library (TKDL), established in 2001 as a collaboration between CSIR and Ministry of AYUSH, is a first-of-its-kind database worldwide designed to prevent Renaissance Grant of patents on Indian traditional knowledge and prevent misappropriation. It contains information on formulations and techniques from Ayurvedic, Siddha, and Unani systems. The database is available in five international languages (English, German, French, Japanese, Spanish) and is accessible only to patent offices that have signed agreements with the Government of India or CSIR. This initiative represents India's proactive approach to protecting its traditional knowledge systems from being patented by foreign entities.

The Traditional Knowledge Digital Library (TKDL) is a comprehensive database managed by the Council of Scientific and Industrial Research (CSIR) in India. It contains encoded information from approximately 34 million pages of ancient texts covering traditional medicine systems including Ayurveda, Yoga, Naturopathy, Unani, Siddha, and Homeopathy. The library translates traditional knowledge into multiple languages (English, French, German, Japanese, Spanish) to help patent examiners identify prior art and prevent wrongful patent grants on traditional knowledge.

In 2001, India built the Traditional Knowledge Digital Library (TKDL), the world's first defensive tool to prevent biopiracy, a joint effort between CSIR and the Ministry of AYUSH. Over 25 years, it has digitized over 500,000 formulations, translated 34 million pages into five international languages, and secured access agreements with 17 patent offices worldwide, resulting in over 265 international patent applications withdrawn, amended, or set aside. Around the TKDL, India has built a multi-layered legal architecture: the Geographical Indications Act of 1999, the Biological Diversity Act of 2002, and Section 3P of the Patents Amendment Act of 2005, which explicitly states that inventions which are merely traditional knowledge are not patentable. Six institutional pillars support this framework, including the Ministry of AYUSH, TKDL, National Biodiversity Authority, and GI Registry.

In 1995, American researchers attempted to patent turmeric for wound healing, a practice Indians had used for centuries. Dr. Ragunath Mashelkar, Director General of CSIR, led a team that spent six months finding 32 pieces of written evidence in ancient Sanskrit texts proving turmeric's healing properties were already documented. In March 1997, the US Patent Office rejected all six claims, and on August 13, 1997, officially revoked the patent—the first time a developing nation successfully challenged a US patent. This victory exposed 'biopiracy'—the theft of traditional knowledge by Western corporations—and led to the creation of the Traditional Knowledge Digital Library (TKDL), a database containing 34 million pages of traditional knowledge translated into five languages, which has since prevented 256 false patents.

Protection of traditional knowledge addresses misappropriation, preserves cultural identity, ensures attribution, enables benefit sharing, protects livelihoods, and requires prior informed consent. Defensive protection creates strategies to prevent illegitimate IP rights by documenting knowledge so it becomes publicly available evidence that such knowledge already exists. The Traditional Knowledge Digital Library (TKDL) is a comprehensive database containing Indian systems of medicine (Ayurveda, Yunani, Siddha, Sowa Rigpa, and Yoga) with over 4.5 lakh formulations from more than 500 books. It correlates vernacular names, botanical names, and modern scientific terminology in multiple languages. The library implements a third party observations system where evidence of existing traditional knowledge is presented to patent examiners, achieving success in approximately 324 cases resulting in patent rejection, amendment, withdrawal, or abandonment.